Last reviewed · How we verify

NCT04574791

Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty

Status unknown NA Last updated 5 October 2020
What this trial tests

NA trial testing TiZANidine 2 MG Oral Capsule in Pain, Postoperative in 240 participants. Status unknown.

Timeline
3 September 2020
Primary endpoint
30 September 2021
30 September 2021

Quick facts

Lead sponsorRothman Institute Orthopaedics
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment240
Start date3 September 2020
Primary completion30 September 2021
Estimated completion30 September 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Rothman Institute Orthopaedics

Who can join

Adults 18 to 80, any sex, with Pain, Postoperative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, cluster-randomized, two-arm, comparative study aimed at determining whether addition of tizanidine ( an oral muscle relaxant) to a multimodal pain regimen following primary TKA reduces opioid consumption.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pain, Postoperative

Currently open trials in the same condition.

Other Rothman Institute Orthopaedics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04574791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing